Discovery and Manufacturing Strategies for Novel, Homogeneous ADC Molecules

Video   Dec 23, 2016

 

Several key learnings have emerged through application of rapid re-iterative ADC design using reactive non-natural amino acids to specifically position conjugation sites: Site-specific homogeneous molecules can improve therapeutic index preclinically and have the potential to optimize clinical impact for a given combination of antibody and warhead. Site matters. Homogeneity is required, but not sufficient, for best in class molecules. Finding the optimal site for conjugation is crucial. Beyond antibody stability, PK and attributes that optimize for internalization and cell killing in vitro, certain conjugation sites on the antibody further enhance solid tumor killing efficacy in vivo. The antibody production process has been split into two stages; First the production of the ribosome-rich extract that can now be considered a critical raw material. And secondly, use of that cell-free extract to produce nnAA containing antibodies in 10 hours from DNA. Each stage has been optimized for speed, efficiency and flexibility and now established as a viable manufacturing process: Removal of RF-1 from the extract permits very efficient production of nnAA containing Use of novel nnAAs allows complete conjugation in minutes Extracts that incorporate orthogonal tRNAs and lack RF-1 provide for efficient and flexible manufacturing.

 
 
 
 

Recommended Videos

Killing Cancer Cells with the Help of Infrared Light

Video

Near-infrared photoimmunotherapy uses an antibody–photoabsorber conjugate that binds to cancer cells. When near-infrared light is applied, the cells swell and then burst, causing the cancer cell to die.

WATCH NOW

Therapeutic Antibodies: Antibody-Drug Conjugates

Video

This is the third video in a three-part series of animations about therapeutic antibodies. This video focuses on antibody-drug conjugates.

WATCH NOW

Lumpy Skin Disease Vaccination Programme in Europe

Video

In January 2016 a number of countries in South East Europe started vaccinating cattle against lumpy skin disease. As the programme has progressed the number of outbreaks has fallen and by the end of 2017 the outbreaks had been contained.

WATCH NOW

 

Comments | 0 ADD COMMENT

Like what you just watched? You can find similar content on the communities below.

Biopharma Immunology & Microbiology

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE